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INTRODUCTION
Testosterone (T) therapy has garnered widespread public enthusiasm and media attention due to
its potential role in age-related T decline in men, commonly known as late-onset hypogonadism
(LOH), andropause, or low T syndrome. The serum T concentration gradually declines across
the lifespan and the symptoms between aging and hypogonadism overlap. These have led to
the speculation that a causal relationship might exists between age-related reduction in serum T
concentration and symptoms commonly seen in aging. However, it remains uncertain if T therapy
could ameliorate symptoms associated with LOH, without significant risks. Despite the lack of
clinical evidence and long term safety data, prescribing rates of T therapy have skyrocketed in many
countries (1, 2), leading to efforts by regulatory authorities to limit such inappropriate prescribing
practice (3).
Importantly, the fundamental question of what constitutes clinically significant LOHwas largely
unaddressed until recently. Heterogeneity in definitions of LOH and the use of specificity-limited
immunoassays for T measurements in many previous epidemiological and interventional studies
have precluded robust comparisons across studies (4). Due to the expanding aging population,
LOH is becoming an increasingly important topic. We reviewed the evidence from recent
population-based studies and intervention trials to provide better understanding of the diagnosis,
pathophysiology, and management for LOH.
PATHOPHYSIOLOGY OF T DECLINE IN AGING
The testicular function undergoes natural decline with age. Compared to younger men, healthy
older men has 40% less Leydig cell mass and a corresponding rise in luteinizing hormone (LH)
concentration (5). Decreased testicular T production was also observed in aged Leydig cells,
following diminished LH-stimulated cAMP production, and reduced downstream steroidogenic
enzymatic activity (6). On the other hand, aging is associated with changes in LH secretory pattern.
A reduced T production and frequent, small irregular LH pulses was observed in healthy older men
(7), despite preservation of pituitary gonadotrophs’ response to exogenous gonadotropin-releasing
hormone (GnRH) (8).This suggests age or factors associated with aging reduced negative feedback
inhibition by T. An ensemble-based analysis also predicted a >30% fall in GnRH output in healthy
older men (9). However, a recent study has demonstrated that healthy older men without late-onset
hypo-gonadism (LOH) have preserved hypothalamic response to kisspeptin-54 and pituitary
response to GnRH, with impaired testicular response as compared to younger men (10). This
suggests that primary testicular failure accounts principally for the normal aging-related decline
in T production. In majority of healthy older men, the compensatory increase in gonadotrophins
serves to maintain T levels within eugonadal ranges (11).
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The pathophysiology of LOH is complicated by comorbidities
associated with aging. The development of chronic illnesses,
including diabetes, cardiovascular disease and inflammatory
disorders, is associated with a contemporaneous accelerated
rate of aging-related T decline, ranging between 1.5- and
3.6-fold compared to men who remain disease-free (12, 13).
Furthermore, excess adiposity exerts potent suppressive effects
on the HPT axis. Individuals with BMI ≥30 kg/m2 are at
13-fold increased risk of LOH compared to those with BMI
<25 kg/m2 (14). Overall, men with comorbidity and/or obesity
failed to exhibit compensatory rise in LH levels which would
otherwise expected in healthy non-obese men suggesting a
significant disruption at the hypothalamic-pituitary level which
compromises T production (15).
Consonant with that, obesity has been shown to be the most
common factor associated with the development of low T in
middle-aged and older men (11). The pathogenic role of excess
adiposity has been postulated to be linked to several adipose
tissue-derived factors, including pro-inflammatory cytokines and
leptin, and altered insulin-signaling, which act in concert to
produce central inhibitory effects on the HPT axis, leading
to secondary hypogonadism (16–18). Interesting, obesity also
increase oxidative/nitrosative stress leading to nitroso-redox
imbalance and male sexual dysfunction (19). The potential
mechanisms underpin the development of LOH is depicted
in Figure 1.
AGING-RELATED DECLINE IN T
CONCENTRATIONS
Serum total T concentrations were historically thought to decline
at a rate of 1–2% per annum from 4 to 5th decade onwards
(20, 21). One of the population-based studies demonstrated
that >50% of men aged ≥80 years had T level in hypogonadal
range, as defined by <2.5th percentile for young men (<11.3
nmol/l) (22).
However, accumulating evidence from newer studies suggest
that age-related fall in serum total T is closer to 0.5% per year
(12, 15, 23), and healthy older men actually experience minimal
changes in T levels. A community-based longitudinal study
from South Australia showed that the rate of decline of total
T concentrations in a subset of men without chronic illnesses
was a non-significant 0.27% per year (12). In another study,
no appreciable change in serum T up to 8th decade of life was
observed among men with self-reported very good to excellent
health (24). In European Male Aging Study (EMAS), 2,736 men
aged ≥40 years were followed up for an average of 4.4 years, and
>80% of men in their 7–8th decade continued to have normal
T values (11). Therefore, LOH is less prevalent than previously
thought, and low T in older men is mostly related to co-existing
medical conditions and obesity.
THE CHALLENGES IN DIAGNOSING LOH
LOH has conventionally been defined as low serum T in older
men, irrespective of the luteinizing hormone (LH) levels. This
has led to a prevalence as high as 50% been quoted in some
studies. However, the European Male Aging Study (EMAS) has
demonstrated two distinct groups of older men with low total
T (14). The majority of older men were found to have low T
associated with low-normal luteinizing hormone. This is not
independently associated with aging per se but is mediated
indirectly via age-related non-gonadal co-morbidities, including
obesity, and increased visceral adiposity. Only a small number
of older men (2.1%) had low T with high LH, in keeping
with primary testicular insufficiency. This specific primary
hypogonadism profile has been directly associated with both
aging and metrics of ill health.
On the other hand, it is imperative that the diagnostic
evaluation of male hypogonadism be corroborated with signs and
symptoms (25). However, there is substantial overlap between
symptoms arising from chronic diseases and hypogonadism,
posing significant challenge to determining clinically relevant
LOH (14). Indeed, men reported hypogonadal symptoms
frequently have T concentrations in the eugondal ranges (26).
Moreover, the clinical significance of borderline or modestly low
T levels typically seen in LOH is often hard to ascertain.
To address some of these gaps, EMAS investigators established
a set of minimum criteria (14). In this study, 32 candidate
symptoms were shortlisted, and after reductive analysis, only
the co-occurrence of three sexual symptoms (decreased morning
erection, poor libido, erectile dysfunction) and low T level (total
T < 11 nmol/L and free T < 220 pmol/L) had consistent
syndromic association. With that, the overall prevalence of
LOH in EMAS population was determined to be 2.1%, widely
believed to be the most accurate estimate hitherto, lower than
previous studies using less stringent criteria (26). Stratifying
by age groups, <1% of men aged <60 years, 3.2% of men
aged 60–69 years, and 5.1% of men aged 70–79 years met the
proposed criteria.
THE CLASSIFICATION OF LOH
ACCORDING TO LH LEVEL AND
ASSOCIATED RISK FACTORS
The hypothalamus-pituitary- testicular (HPT) axis is tightly
regulated in an interdependent fashion to maintain hormonal
homeostasis. In hypogonadism, the gonadotropins can either
be elevated (primary hypogonadism) or low/normal (secondary
hypogonadism). In EMAS, subjects are classified into primary
hypogonadism (LH > 9.4 u/L, T < 10.5 nmol/L), secondary
hypogonadism (LH≤ 9.4 u/L, T< 10.5 nmol/L) or compensated
(primary) hypogonadism (LH > 9.4 u/L, T ≥ 10.5 nmol/L) (11).
Through this approach, unique clinical characteristics and risk
factors were identified in each subgroup.
Primary hypogonadism was found to be uncommon in the
study. It affected only 2% of the entire cohort and had a
low annual incidence of 0.2% (27). At-risk men had poorer
baseline physical function, and suffered from deterioration in
erectile function, vigor and hemoglobin as they progressed to
hypogonadism. Advanced age (>70 years) and comorbidities
were strongly associated with increased risk of primary
hypogonadism, with an odds ratio of 12.5 and 4.24, respectively.
The serum T concentrations continued to decline with time
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FIGURE 1 | Mechanistic explanation for low serum T in middle-aged and older men. (A) As Leydig cell reserve decline with aging, compensatory rise in luteinising
hormone (LH) occurs to maintain circulating testosterone (T) concentrations (compensated hypogonadism). In more advanced state, elevated LH can no longer
overcome the diminished testicular function, leading to overtly low T levels (primary hypogonadism). (B) Obesity is the predominant cause of functional suppression of
hypothalamic-pituitary-testicular (HPT) axis in middle-aged and older men, manifesting as failure of LH response to low T (secondary hypogonadism). Multimorbidity is
also associated with both primary and secondary hypogonadism, albeit to a lesser degree. Excess adiposity has been linked to altered insulin signaling, oxidative
stress and increased pro-inflammatory cytokines and leptin levels, which act in concert to suppress the central HPT axis. Adipose tissues also express aromatase
which convert testosterone to estradiol, especially in the inflammed state, exerting inhibitory effects on the HPT axis.
with little sign of recovery. For the minority whom T levels
returned to eugonadal range, the mean LH levels remained
persistently elevated to the same degree, indicating persistent
Leydig cell failure.
Secondary hypogonadism accounted for majority (85.5%) of
older men with low T, with an annual incidence of 1.6% (11).
The mean LH level was not different from that of eugonadal
men, indicating a failure in the compensatory hypothalamic-
pituitary axis. Unlike primary hypogonadism, there was no
significant relationship between the prevalence of secondary
hypogonadism and aging. Instead, obesity emerged to be the
most potent risk factor (14, 15), with a lesser contribution by
comorbidities. Therefore, secondary hypogonadism represents a
state of functional HPT suppression driven principally by obesity
and poor health, rather than chronological aging.
The third classification was compensated hypogonadism,
present in close to 10% of the study cohort. This group of men
had normal circulating total T concentration and raised LH level.
They exhibited some clinical features in keeping with primary
hypogonadism (27), making it a clinically relevant entity. Despite
being relatively common, progression to hypogonadism range of
T concentration was very infrequent, suggesting thatmostmen in
this group could retain the capacity to sustain adequate T levels.
MANAGEMENT OF LOH
Subtyping LOH according to both T and LH levels provides
useful clinical information in elucidating the underlying etiology,
and allows management to be tailored accordingly. For LOH
due to testicular failure (primary hypogoadism), T treatment
could be used to improve anemia, sexual activity and libido
in older men (28–34). However, T therapy was found to
have no significant impact on energy level, physical function,
weight, or cognitive function among older men with LOH
(28, 35–40). Despite the reassuring data from majority of
interventional trials with regards to short term safety (41–44),
a meta-analysis of 27 placebo-controlled trials has concluded
that T therapy was associated with an increased cardiovascular
risk, with an odds ratio of 1.54 (95% confidence interval,
1.09 to 2.18) (45). Furthermore, T therapy is associated with
increased hematocrit, serum concentrations of prostate-specific
antigen (PSA) and prostate volume, as well as gynecomastia and
secondary infertility. Hence, T therapy should only be considered
after careful consideration of the risks and benefits, while bearing
in mind that the cardiovascular safety profile of T therapy in this
population has yet to be fully established. Ongoing surveillance
of hematocrit and prostate specific antigen is also required whilst
on T treatment (24).
On the other hand, human chorionic gonadotropin (HCG)
may have a therapeutic role in LOH (46, 47). HCG therapy
is known to increase serum testosterone concentration and
preserve global activity of the testis (e.g., fertility and insulin-
like factor 3 production) (48, 49). A clinical trial comparing 6-
months HCG vs. T therapy in LOH has demonstrated higher
25-OH-vitamin D and lower serum estradiol concentrations in
men treated with HCG (47). The prostate volume and hematocrit
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level were also significantly lower compared to the groups treated
with T (47). The Leydig cells have been shown to contribute to
the 25-hydroxylation of vitamin D and a higher 25-OH-vitamin
D level may reflect improved Leydig cell function following HCG
treatment (50). Hence, HCG therapy may have a favorable profile
in LOH but larger safety and efficacy trials would be required to
determine if HCG could be used as a long-term therapy in LOH.
It should be emphasized that obesity and co-morbidities
underlies most cases of low T in older men with secondray
hypogonadism, and thus, lifestyle intervention and
cardiometabolic risk reduction should be the first line treatment
for this cohort of patients. Notably, the potential for reversal to
eugonadism in secondary hypogonadism is promising for obese
men; nearly half of the men recovered their T levels over a period
of∼4 years, predicted by attainment of healthier weight (51).
CONCLUSION
Establishing the diagnosis of LOH remains a conundrum in
clinical practice because of imprecise criteria and confounding
factors relating to health alterations in old age. Nonetheless, if
we define LOH as age-related primary testicular failure, only
a minority of men appears to be affected. While studies have
demonstrated some positive effects of T therapy, the clinical
meaningfulness of these findings remains debatable. Moreover,
the absence of long-term cardiovascular safety data continues to
be an area of concern and controversy.
Hence, we suggest that future interventional trials for LOH
should aim at older men with primary testicular failure, or
classify the study cohorts according to LH levels so that a more
clinically meaningful risk-benefit stratification can be elicited.
This will clarify the safety and benefit profile of T therapy or other
treatments in LOH and inform decision of the most appropriate
management for LOH in men.
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